LONDON — The UK government has officially finalized the legal text of the U.K.-U.S. pharmaceutical agreement, ensuring a commitment to enhance the National Health Service (NHS) spending on new medications in return for an elimination of tariffs.
Strengthening the special relationship
This agreement marks a significant moment in the ongoing dialogue between the U.K. and the U.S., particularly in light of recent tensions. President Donald Trump has expressed dissatisfaction with Britain over its reluctance to participate in military actions against Iran and has even threatened to withdraw U.S. support from NATO.
Under the terms of the deal announced last December, the U.K. will increase the cost-effectiveness threshold utilized by the National Institute for Health and Care Excellence (NICE) by 25 percent. Concurrently, the maximum rebate the NHS can reclaim from pharmaceutical companies is set to be reduced to 15 percent.
Commitment to future healthcare funding
In an announcement made on Thursday, the government confirmed it has reached an agreement with the U.S. that includes a three-year exemption for the U.K. from tariffs on pharmaceuticals and medical technology. Additionally, both nations have committed to collaborating on the mutual recognition of medical device approvals.
The U.K. has set a target to increase pharmaceutical spending to 0.6 percent of its GDP by 2035. Industry leaders view this agreement as a crucial step in establishing a credible timeline for achieving this spending goal. They are optimistic that the new framework will facilitate more investment in healthcare.
The oversight committee, led by Science Minister Patrick Vallance and Medicines Minister Zubir Ahmed, is actively developing a strategy to implement these increased funding levels effectively.
“Thanks to this partnership, patients right across the NHS will benefit from access to life changing new medicines that they previously would have been denied,” said Vallance. “Not only this, but as the first country in the world to benefit from a zero percent tariff on pharmaceuticals to the US, Britain’s life sciences sector will be further boosted.”
Earlier last month, the government introduced secondary legislation to amend the assessment criteria for new drugs evaluated by NICE, increasing the cost-effectiveness threshold by £5,000, bringing it to between £25,000 and £35,000 per quality-adjusted life year.